Literature DB >> 24101153

Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling.

Yi Qu1, Anne Margrete Oyan, Runhui Liu, Yaping Hua, Jigang Zhang, Randi Hovland, Mihaela Popa, Xiaojun Liu, Karl A Brokstad, Ronald Simon, Anders Molven, Biaoyang Lin, Wei-dong Zhang, Emmet McCormack, Karl-Henning Kalland, Xi-Song Ke.   

Abstract

How prostate cancer is initiated remains a topic of debate. In an effort to establish a human model of prostate carcinogenesis, we adapted premalignant human prostate EPT2-D5 cells to protein-free medium to generate numerous tight prostate spheres (D5HS) in monolayer culture. In contrast to EPT2-D5 cells, the newly generated D5HS efficiently formed large subcutaneous tumors and subsequent metastases in vivo, showing the tumorigenicity of D5HS spheres. A striking production of interleukin (IL)-6 mRNA and protein was found in D5HS cells. The essential roles of IL-6 and the downstream STAT3 signaling in D5HS tumor sphere formation were confirmed by neutralizing antibody, chemical inhibitors, and fluorescent pathway reporter. In addition, elevated reactive oxygen species (ROS) produced upon protein depletion was required for the activation of IL-6/STAT3 in D5HS. Importantly, a positive feedback loop was found between ROS and IL-6 during tumor sphere formation. The association of ROS/IL-6/STAT3 to the carcinogenesis of human prostate cells was further examined in xenograft tumors and verified by limiting dilution implantations. Collectively, we have for the first time established human prostate tumor-initiating cells based on physiologic adaption. The intrinsic association of ROS and IL-6/STAT3 signaling in human prostate carcinogenesis shed new light on this relationship and define therapeutic targets in this setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24101153     DOI: 10.1158/0008-5472.CAN-13-1560

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer.

Authors:  Yi Qu; Jan Roger Olsen; Xing Yuan; Phil F Cheng; Mitchell P Levesque; Karl A Brokstad; Paul S Hoffman; Anne Margrete Oyan; Weidong Zhang; Karl-Henning Kalland; Xisong Ke
Journal:  Nat Chem Biol       Date:  2017-10-30       Impact factor: 15.040

Review 2.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

3.  Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties.

Authors:  Yong-Qing Liu; Shi-Kang Wang; Qing-Qing Xu; Hui-Qing Yuan; Yan-Xia Guo; Qian Wang; Feng Kong; Zhao-Min Lin; De-Qing Sun; Rong-Mei Wang; Hong-Xiang Lou
Journal:  Acta Pharmacol Sin       Date:  2018-08-31       Impact factor: 6.150

4.  Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer.

Authors:  Yi Qu; Naouel Gharbi; Xing Yuan; Jan Roger Olsen; Pernille Blicher; Bjørn Dalhus; Karl A Brokstad; Biaoyang Lin; Anne Margrete Øyan; Weidong Zhang; Karl-Henning Kalland; Xisong Ke
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

5.  Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.

Authors:  J Wang; T R McGuire; H C Britton; J K Schwarz; F R Loberiza; J L Meza; J E Talmadge
Journal:  Clin Exp Metastasis       Date:  2015-01-25       Impact factor: 5.150

Review 6.  Role of JAK-STAT and PPAR-Gamma Signalling Modulators in the Prevention of Autism and Neurological Dysfunctions.

Authors:  Rishabh Khera; Sidharth Mehan; Sumit Kumar; Pranshul Sethi; Sonalika Bhalla; Aradhana Prajapati
Journal:  Mol Neurobiol       Date:  2022-04-18       Impact factor: 5.590

Review 7.  Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer.

Authors:  Madhuvanthi Giridharan; Vasu Rupani; Satarupa Banerjee
Journal:  ACS Pharmacol Transl Sci       Date:  2022-03-30

8.  Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain.

Authors:  Yaping Hua; Xing Yuan; Yun-Heng Shen; Jinxin Wang; Waqas Azeem; Shuo Yang; Alexandra Gade; Seyed Mohammad Lellahi; Anne Margrete Øyan; Xisong Ke; Wei-Dong Zhang; Karl-Henning Kalland
Journal:  Front Pharmacol       Date:  2022-05-27       Impact factor: 5.988

9.  Interleukin-6 Function and Targeting in Prostate Cancer.

Authors:  Zoran Culig
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 10.  Precision Medicine Gains Momentum: Novel 3D Models and Stem Cell-Based Approaches in Head and Neck Cancer.

Authors:  Annette Affolter; Anne Lammert; Johann Kern; Claudia Scherl; Nicole Rotter
Journal:  Front Cell Dev Biol       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.